Insights

Why the Starpharma (ASX:SPL) share price is tumbling lower today

The Starpharma Holdings Limited (ASX:SPL) share price is tumbling lower on Tuesday despite the release of a positive announcement…
The post Why the Starpharma (ASX:SPL) share price is tumbling lower today appeared first on The Motley Fool Australia. –

a trader on the stock exchange holds his head in his hands, indicating a share price drop

The Starpharma Holdings Limited (ASX: SPL) share price has come under pressure on Tuesday despite the release of a positive announcement.

In afternoon trade, the dendrimer products developer’s shares are down 4.5% to $1.99.

What did Starpharma announce?

This morning Starpharma announced that its Viraleze antiviral nasal spray has now been launched in the UK by LloydsPharmacy.

Viraleze is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013), which is virucidal and irreversibly inactivates >99.9% of the virus that causes COVID-19 within one minute.

The company also notes that SPL7013 has been shown to be highly active against multiple strains of COVID-19, as well as a broad spectrum of other viruses. These include influenza, RSV, SARS, MERS, and HIV.

What now?

According to the release, Viraleze is now available for purchase in the UK online at LloydsPharmacy and will soon be launched instore.

At present, LloydsPharmacy plans to rollout Viraleze to their 1,400 UK pharmacies in April. It will also be made available through McKesson’s AAH wholesale division, which services a total of 14,000 independent pharmacies in the UK.

But the company won’t be stopping there. Starpharma also plans to roll the product out across Europe, and will seek registration for the product in other regions, including Australia.

Commenting on the deal with LloydsPharmacy and McKesson last week, Starpharma’s CEO, Dr Jackie Fairley, revealed that the company was very excited with the launch.

She said: “We are excited that VIRALEZE will be available from next week in the second largest pharmacy chain in the UK. The LloydsPharmacy/McKesson team shares Starpharma’s enthusiasm and commitment to bring VIRALEZE antiviral nasal spray to UK consumers as they emerge from their latest lockdown. LloydsPharmacy represents an ideal partner for this product.”

Why is the Starpharma share price tumbling lower?

While the above is a big positive, it was already largely factored in by the market following its previous announcement.

In light of this, investors may be taking a bit of profit off the table today after a strong gain by the Starpharma share price this year.

In fact, even after today’s decline, the Starpharma share price is up 30% since the start of the year.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Starpharma (ASX:SPL) share price is tumbling lower today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!